Nova Eye Medical Limited (ELXMF) Shareholder/Analyst Call Transcript
Summarize this article with:
SA Transcripts158.76K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Nova Eye Medical Limited (ELXMF) Shareholder/Analyst Call March 2, 2026 7:30 PM EST Company Participants Mark Flynn - Investor RelationsThomas Spurling - MD & Executive Director Presentation Mark FlynnInvestor Relations Good morning, everyone. And once again, thank you for joining us. Welcome to the Nova Eye Medical Investor webinar covering our half year results for the 6 months ended 31 December 2025, along with an update that we put out this morning on our recent EU MDR certification. My name is Mark Flynn. I look after Investor Relations at Nova Eye. Today, as usual, our Managing Director, Thomas Spurling, will walk us through the key financial outcomes from the half, the continued momentum we have in the U.S., margin and EBITDA progression, cash flow and obviously, the outlook for the second half for FY '26. We'll cover the strategic importance of securing that EU MDR certification, which is a big and major regulatory milestone for the company and supports our ongoing commercial activities in Europe and elsewhere. So as always, there will be time for Q&A at the end of the presentation, so you can submit your questions at any time through the webinar using the Q&A function in Zoom. I have received other questions via e-mail, which I will be asking. With that, I'll hand over to Tom. Thomas SpurlingMD & Executive Director Thanks, Mark, and thanks, everybody. We've had a few webinars over the last month or 2, and I appreciate everybody sitting in and listening. We have an exciting company. At the end of today, I would like you all to think of the three reasons that we like Nova Eye. First of all, we are operating in a big market with endless supply of customers, point one. Point two, our company over the years has built infrastructure and a position in that market, which is very valuable and